Skip to main content
Clinical Trials/NCT01035307
NCT01035307
Completed
Not Applicable

Genomic and Proteomic Profiling of Childhood AML

Children's Oncology Group0 sites90 target enrollmentOctober 2009
ConditionsLeukemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leukemia
Sponsor
Children's Oncology Group
Enrollment
90
Primary Endpoint
Profiling of basal and potentiated phospho-protein networks (PPPNs) using tissue samples
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial POG-9421.

Detailed Description

OBJECTIVES: * To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled on clinical trial POG-9421. * To classify AML-based signal transduction mechanisms. * To correlate profiles of basal and PPPNs with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene expression in tumor tissue samples. OUTLINE: Banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.

Registry
clinicaltrials.gov
Start Date
October 2009
End Date
May 2016
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Profiling of basal and potentiated phospho-protein networks (PPPNs) using tissue samples

Classification of AML-based signal transduction mechanisms

Correlation of basal and PPPN profiles with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and gene expression profiles.

Similar Trials